BR112016002435A2 - proteínas biomarcadoras da síndrome urêmica hemolítica atípica - Google Patents

proteínas biomarcadoras da síndrome urêmica hemolítica atípica

Info

Publication number
BR112016002435A2
BR112016002435A2 BR112016002435A BR112016002435A BR112016002435A2 BR 112016002435 A2 BR112016002435 A2 BR 112016002435A2 BR 112016002435 A BR112016002435 A BR 112016002435A BR 112016002435 A BR112016002435 A BR 112016002435A BR 112016002435 A2 BR112016002435 A2 BR 112016002435A2
Authority
BR
Brazil
Prior art keywords
ahus
biomarker proteins
uremic syndrome
treatment
hemolytic uremic
Prior art date
Application number
BR112016002435A
Other languages
English (en)
Other versions
BR112016002435A8 (pt
Inventor
Kukreja Anjli
A Bedard Krystin (Falecida)
Cofiell Roxanne
Faas Mcknight Susan
Yan Yan
Original Assignee
Alexion Pharmeceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmeceuticals Inc filed Critical Alexion Pharmeceuticals Inc
Priority to BR122020019190-2A priority Critical patent/BR122020019190B1/pt
Publication of BR112016002435A2 publication Critical patent/BR112016002435A2/pt
Publication of BR112016002435A8 publication Critical patent/BR112016002435A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/7452—Thrombomodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a divulgação fornece proteínas biomarcadoras, uma mudança na concentração ou nível de atividade das quais está associada com a síndrome urêmica hemolítica atípica (ahus) ou tratamento clinicamente significativo de ahus com um inibidor de complemento. também são fornecidos composições e métodos para apurar a concentração e/ou atividade de uma ou mais das proteínas biomarcadoras em um fluído biológico. as composições e métodos são úteis, entre outras coisas, para avaliar o risco de desenvolver ahus, diagnosticar ahus, determinar se um indivíduo está experienciando a primeira apresentação aguda de ahus, monitorar a progressão ou diminuição de ahus, e/ou monitorar a resposta ao tratamento com um inibidor de complemento ou otimizar tal tratamento.
BR112016002435A 2013-08-07 2014-08-06 proteínas biomarcadoras da síndrome urêmica hemolítica atípica BR112016002435A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020019190-2A BR122020019190B1 (pt) 2013-08-07 2014-08-06 Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863299P 2013-08-07 2013-08-07
US201361913180P 2013-12-06 2013-12-06
PCT/US2014/049957 WO2015021166A2 (en) 2013-08-07 2014-08-06 Atypical hemolytic uremic syndrome biomarker proteins

Publications (2)

Publication Number Publication Date
BR112016002435A2 true BR112016002435A2 (pt) 2017-09-12
BR112016002435A8 BR112016002435A8 (pt) 2020-09-29

Family

ID=51358124

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016002435A BR112016002435A8 (pt) 2013-08-07 2014-08-06 proteínas biomarcadoras da síndrome urêmica hemolítica atípica
BR122020019190-2A BR122020019190B1 (pt) 2013-08-07 2014-08-06 Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020019190-2A BR122020019190B1 (pt) 2013-08-07 2014-08-06 Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus

Country Status (14)

Country Link
US (5) US20150079613A1 (pt)
EP (3) EP3290922A1 (pt)
JP (3) JP6211701B2 (pt)
KR (3) KR102448976B1 (pt)
CN (1) CN105683759B (pt)
AU (1) AU2014306002B2 (pt)
BR (2) BR112016002435A8 (pt)
CA (1) CA2918959C (pt)
EA (1) EA034870B1 (pt)
ES (1) ES2650917T3 (pt)
HK (1) HK1218443A1 (pt)
IL (1) IL243653B (pt)
SI (1) SI3011345T1 (pt)
WO (1) WO2015021166A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011220413B2 (en) * 2010-02-26 2015-07-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins
JP6654137B2 (ja) 2013-09-16 2020-02-26 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
IL229134A0 (en) * 2013-10-29 2014-03-31 Omrix Biopharmaceuticals Ltd Compounds and methods for stabilizing thrombin activity
ES2898424T3 (es) * 2015-03-29 2022-03-07 Endothel Pharma Aps Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
KR102534895B1 (ko) 2016-06-14 2023-05-24 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
ES2848206T3 (es) * 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
EP3532845A1 (en) 2016-10-27 2019-09-04 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
US10765762B2 (en) * 2017-02-27 2020-09-08 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR20240019857A (ko) 2017-03-01 2024-02-14 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
EP3717004A4 (en) * 2017-12-01 2021-12-01 Children's Hospital Medical Center COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE
AU2018383751A1 (en) 2017-12-13 2020-06-25 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
JP2021526534A (ja) * 2018-06-04 2021-10-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
CN112839945A (zh) 2018-09-06 2021-05-25 艾其林医药公司 补体因子d抑制剂的形态形式
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
WO2021153649A1 (ja) * 2020-01-31 2021-08-05 公立大学法人大阪 造血幹細胞移植後の合併症リスクの検出方法、予測診断薬及びキット
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US11940450B2 (en) * 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
WO2022251446A1 (en) * 2021-05-28 2022-12-01 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
GB9007971D0 (en) 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2097825A1 (en) 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
AU685433B2 (en) 1993-02-12 1998-01-22 Regents Of The University Of Minnesota Pulmonary administration of sCR1 and other complement inhibitory proteins
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
ES2317689T3 (es) 1998-02-20 2009-04-16 Genentech, Inc. Inhibidores de la activacion del complemento.
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2001058526A2 (en) 2000-02-10 2001-08-16 Alexion Pharmaceuticals, Inc. Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
DE60118023T2 (de) 2000-12-05 2006-12-28 Alexion Pharmaceuticals, Inc., Cheshire Rationell entworfene antikörper
EP2325205A3 (en) 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
AU2003223288A1 (en) 2002-03-18 2003-10-08 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
NZ538384A (en) 2002-09-06 2009-04-30 Alexion Pharma Inc Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US8329169B2 (en) * 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US20050036691A1 (en) 2003-08-13 2005-02-17 Pascal Cathier Method and system for using structure tensors to detect lung nodules and colon polyps
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
ES2528362T3 (es) 2004-05-14 2015-02-09 Alexion Pharmaceuticals, Inc. Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento
US20070092911A1 (en) * 2005-10-03 2007-04-26 Buechler Kenneth F Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2007038995A1 (en) 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
PL2044111T3 (pl) 2006-06-21 2015-02-27 Musc Found For Res Dev Celowanie czynnika H dopełniacza do leczenia chorób
AU2007313170A1 (en) 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
CL2007003161A1 (es) 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
US20100120665A1 (en) 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
WO2008140653A2 (en) 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
WO2008154251A2 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2008153962A2 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennylvania Method of reducing tissue loss in pancreatic islet cell transplantation
AU2008293487A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
AR069130A1 (es) 2007-11-02 2009-12-30 Novartis Ag Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
PT2262831E (pt) 2008-03-03 2015-05-18 Novelmed Therapeutics Inc Anticorpos antiproperdina
EP2328616B1 (en) 2008-08-05 2015-04-29 Novartis AG Compositions and methods for antibodies against complement protein c5
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
WO2010057084A1 (en) * 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Method of treating ischemia reperfusion injury
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
BRPI1012759A2 (pt) * 2009-06-23 2019-07-02 Alexion Pharma Inc anticorpos biespecíficos que se ligam as proteínas do complemento.
US9562905B2 (en) * 2009-07-29 2017-02-07 Radox Laboratories Limited Method for detection of, or the risk of, bladder cancer
BR112012027900A2 (pt) * 2010-04-30 2020-05-12 Alexion Pharmaceuticals, Inc. Anticorpos anti-c5a e métodos para usar os anticorpos
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
CN102539745B (zh) * 2010-12-31 2013-03-06 中国人民解放军第三〇九医院 移植肾排斥反应早期诊断及预警试剂盒
AU2013201626B2 (en) * 2011-04-08 2016-02-11 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins

Also Published As

Publication number Publication date
AU2014306002B2 (en) 2017-05-25
WO2015021166A2 (en) 2015-02-12
SI3011345T1 (sl) 2017-12-29
CN105683759B (zh) 2019-03-29
BR112016002435A8 (pt) 2020-09-29
US20170269102A1 (en) 2017-09-21
US20210285964A1 (en) 2021-09-16
JP6798934B2 (ja) 2020-12-09
JP2021009162A (ja) 2021-01-28
ES2650917T3 (es) 2018-01-23
US9658236B2 (en) 2017-05-23
CA2918959C (en) 2024-05-07
HK1218443A1 (zh) 2017-02-17
JP2016528235A (ja) 2016-09-15
IL243653B (en) 2019-01-31
WO2015021166A3 (en) 2015-05-07
BR122020019190B1 (pt) 2023-11-21
EA201690346A1 (ru) 2016-08-31
CN105683759A (zh) 2016-06-15
EP4300103A2 (en) 2024-01-03
JP2017142266A (ja) 2017-08-17
US9494601B2 (en) 2016-11-15
EP3011345B1 (en) 2017-10-04
EP4300103A3 (en) 2024-02-28
US20160154009A1 (en) 2016-06-02
EP3290922A1 (en) 2018-03-07
CA2918959A1 (en) 2015-02-12
KR102192596B1 (ko) 2020-12-18
AU2014306002A1 (en) 2016-02-18
IL243653A0 (en) 2016-03-31
JP6211701B2 (ja) 2017-10-11
KR20200066743A (ko) 2020-06-10
KR20160033230A (ko) 2016-03-25
KR102448976B1 (ko) 2022-09-29
US20150079613A1 (en) 2015-03-19
JP7235709B2 (ja) 2023-03-08
KR20180026555A (ko) 2018-03-12
KR101834469B1 (ko) 2018-03-06
EA034870B1 (ru) 2020-03-31
US20170023590A1 (en) 2017-01-26
EP3011345A2 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
BR112016002435A2 (pt) proteínas biomarcadoras da síndrome urêmica hemolítica atípica
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
BR112017005730A8 (pt) Predição de evento de risco cardiovascular e usos da mesma
BR112019022538A8 (pt) Técnicas para pareamento comportamental em um sistema de centro de contato
BR112018070971A2 (pt) métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
BR112016004963A2 (pt) biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença
BR112013027122A2 (pt) método e sistema para analisar características de tecido, e, kit
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
BR112014019131A8 (pt) Aparelho de processamento de informação, e, mídia legível por computador
BR122019023720A8 (pt) Kit de triagem de um indivíduo em uma população por meio de avaliação ou prognóstico do risco de um evento cardiovascular futuro dentro de um período de 5 anos
BR112015003975A2 (pt) método de manuseio de mensagens e terminal que suporta o mesmo
BR112018015698A2 (pt) ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos?
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
BR112015004800A2 (pt) método e aparelho para examinar ovos
BR102012002812A8 (pt) método para determinar a influência de uma variável em um fenômeno
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR102014001786A8 (pt) Método de comunicar dados entre pelo menos dois coprocessadores em um único ambiente
BR112015024735A2 (pt) dispositivo de auto-avaliação, kit, embalagem para uma composição de tratamento capilar e método de avaliação do estado do cabelo
BR112014025189A2 (pt) prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica
BR112015017099A2 (pt) transmissão de sinal de referência a partir de múltiplas células em modo suspenso
BR112014015498A8 (pt) método; sistema; e meio de armazenamento legível em computador não transitório

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ALEXION PHARMECEUTICALS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]